Therefore, in cancer settings, where tumors elude immune responses and induce angiogenesis or in pathogen-driven inflammatory processes in which GAL-1, GAL-3 or GAL-9 levels are increased, endothelial CD146 can be recognized by one or more of these galectins (Fig. 6). Here, GAL is linked to cancer.